Holen Sie sich die Stockscreener-App
1.99
0.00%
0.00
Vorhandelsmarkt:
2.06
0.07
+3.52%
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
Jobs Data: Can ProQR Therapeutics NV withstand a market correctionQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
Stock Analysis: Can ProQR Therapeutics NV outperform under higher oil prices2026 Short Interest & Precise Trade Entry Recommendations - baoquankhu1.vn
Volume Report: Is ProQR Therapeutics NV currently under institutional pressure2026 Gainers & Expert Verified Movement Alerts - baoquankhu1.vn
Chardan Capital Maintains ProQR Therapeutics N.V. (PRQR) Buy Recommendation - MSN
If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan
ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha
PRQR: Chardan Capital Maintains Buy Rating with $4.00 Price Targ - GuruFocus
Proqr Therapeutics expands early-stage pipeline - BioWorld News
ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital - MarketBeat
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter - Defense World
Aberdeen Group Boosts Stake in ProQR Therapeutics - National Today
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR - MarketBeat
ProQR (PRQR) Partners with Ginkgo Bioworks to Boost AI-Driven Dr - GuruFocus
ProQR partners with Ginkgo on AI drug discovery platform By Investing.com - Investing.com Australia
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR updates RNA editing pipeline, targets biliary atresia By Investing.com - Investing.com Australia
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks - Intellectia AI
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs - TipRanks
ProQR updates RNA editing pipeline, targets biliary atresia - Investing.com
Pipeline expansion and cash runway into 2027 for ProQR (PRQR) - Stock Titan
ProQR picks rare liver disease for lead drug as more data nears - Stock Titan
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst CallSlideshow (NASDAQ:PRQR) 2026-04-08 - Seeking Alpha
ProQR Therapeutics N.V. Establishes AI Advisory Board - marketscreener.com
ProQR in pact with Ginkgo as part of AI strategy (PRQR:NASDAQ) - Seeking Alpha
ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery - TipRanks
ProQR announces partnership with Ginkgo Bioworks and formation of AI advisory board - marketscreener.com
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board - The Manila Times
ProQR partners with Ginkgo on AI drug discovery platform - Investing.com
AI deal with Ginkgo boosts ProQR (NASDAQ: PRQR) Axiomer RNA editing plans - Stock Titan
PRQR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PROQR THERAPEUTICS NV PB Ratio: 3.11 — Near Median - gurufocus.com
Analysts Set $6.80 Price Target for ProQR Therapeutics - National Today
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What analysts say about ProQR Therapeutics NV stockWeekly Trend Recap & Expert Verified Movement Alerts - baoquankhu1.vn
US Market Recap: Can ProQR Therapeutics NV benefit from deglobalization2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Aug Reactions: Can ProQR Therapeutics NV weather a recessionMarket Growth Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn
PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
Retail Trends: Will ProQR Therapeutics NV stock recover after earningsIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - The Globe and Mail
Price Action: Is ProQR Therapeutics NV attractive for institutional investors2026 Pullback Review & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance
ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 - GlobeNewswire
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN
Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World
ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan
ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan
Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan
ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan
ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan
Theresa Heggie (PRQR) details option and share holdings in Form 3 - Stock Titan
ProQR Therapeutics N.V. (PRQR) director files Form 3 for options - Stock Titan
ProQR (PRQR) CEO Daniel de Boer details long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director reports five long-dated option grants - Stock Titan
ProQR Therapeutics (PRQR) director discloses share and option holdings - Stock Titan
Q2 Earnings Estimate for PRQR Issued By HC Wainwright - MarketBeat
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):